The active substance aclidinium bromide is available in the EU under the trade names Eklira Genuair® and Bretaris Genuair®. The drug is approved for the symptomatic bronchodilator prolonged treatment of adults with chronic obstructive pulmonary disease (COPD).
It improves symptoms like chronic cough and shortness of breath. It is taken as a dry powder via a Genuair inhaler at a common rate of twice a day. The drug is suitable for a long-lasting therapy. The long-acting drug expands the bronchi and has parasympathetic properties.
Aclidinium bromide is rapidly absorbed by the lungs. It usually works within 15 minutes. This makes it a good therapy for chroniclers. As a long-acting bronchodilator, however, it is not an emergency situation in question. Likewise, it is not suitable as an asthma medication.
Aclidinium bromide improves lung function and is used in adults to treat COPD. The effects of the administration of aclidinium bromide are shown in bronchodilatory and parasympatholytic ways. An initial relief of the symptoms occurs within 15 minutes after inhalation.
The action of aclidinium bromide is based on antagonism of muscarinic receptors within the respiratory tract. Aclidinium bromide binds longer to M3 receptors (muscarinic receptors M3) and shorter to M2 receptors (muscarinic receptors M2). M3 receptors are responsible for the smooth muscle contractions in the airways.
If this function is blocked by the administration of Aclidiniumbromid, there is a longer lasting inhibition of bronchoconstriction caused by acetylcholine. In plasma, aclidinium bromide is rapidly hydrolyzed to an inactive alcohol metabolite and a carboxylic acid metabolite, reducing the risk of possible side effects outside the lungs.
As an anticholinergic agent, the administration of aclidinium bromide may affect the heart and blood vessels. Therefore, possible cardiovascular effects should be closely monitored. In patients with certain pre-existing diseases of the cardiovascular system Aclidiniumbromid should be used with great caution.
As is generally the case with inhalation treatments, inhalation of aclidinium bromide may lead to paradoxical bronchospasm. In such case, discontinue treatment immediately and contact the doctor.
In chronic obstructive pulmonary disease - in short: COPD - the lungs are permanently damaged. The airways - the bronchi - are chronically constricted, making breathing difficult. Bronchial dilating drugs - called bronchodilators - provide relief from the discomfort. There are two types of bronchodilators: long-acting for long-term use and short-acting for use in acute respiratory distress.
Aclidinium bromide is available as a long-acting bronchodilator. The drug inhibits acetylcholine, an endogenous messenger substance, expanding the airways. It helps against symptoms of respiratory distress and chronic cough. Aclidinium bromide is taken as a dry powder via a reusable Genuair inhaler twice a day at a dose of 375 μg.
The device comes ready filled in the sale and can be used immediately. The effect occurs within 15 minutes after inhalation. Because it is used twice daily, aclidinium bromide is also excellent for patients with symptoms that increase at night or at the beginning of the day.
In up to 10% of patients treated with aclidinium bromide the most common side effects were:
Aclidinium bromide should be used with extreme caution in certain cardiovascular diseases, for example:
Also, caution should be exercised with aclidinium bromide therapy for existing narrow-angle glaucoma, benign prostate enlargement and urinary obstruction in the bladder neck.
Aclidinium bromide is contraindicated in patients with hypersensitivity to the drug and related structure parasympatholytics.
Pregnant women should only take this medicine if the expected benefit exceeds potential risks. Breastfeeding is discouraged from use. Tags: